Goldman Sachs Invests $37M In Venture-Backed Venus Medtech

Login to View

Goldman Sachs has agreed to invest US$37 million in Venus Medtech, a Hangzhou-based healthcare company focused on research and development of heart valves disease related medical products and services, according to a company announcement.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access Over 11,000 stories and data posts over the past 8 years!

Register Now

Already have an account or paid subscription? Log in

Join China Money Network for $89 a month